Atlas Trials

Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

Clinical trial NCT05127174 · TERMINATED

Trial details

NCT number
NCT05127174
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Myeloproliferative Neoplasm
Start date
2022-03-14
Primary completion
2025-01-03
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.